苯溴马隆联合别嘌呤醇对痛风稳定期患者血尿酸水平的影响

EFFECTS OF BENZBROMARONE COMBINED ALLOPURINOL ON BLOOD URIC ACID LEVEL FOR TREATING PATIENTS WITH STABLE GOUT

目的:观察苯溴马隆联合别嘌呤醇治疗痛风稳定期对患者血尿酸水平的影响。方法:136例痛风稳定期患者,随机分为对照组(单纯给予别嘌呤醇治疗)和观察组(给予别嘌呤醇联合苯溴马隆治疗),每组68例患者,两组均连续用药治疗8周。分别检测两组患者治疗前后血尿酸水平、血小板和白细胞计数,并记录治疗期间两组患者不良反应发生情况。结果:治疗后,观察组患者的血尿酸水平明显低于对照组,血小板和白细胞计数明显高于对照组(P<0.05);治疗期间两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:苯溴马隆联合别嘌呤醇治疗痛风稳定期能显著降低患者血尿酸水平,且不增加不良反应,值得临床推广。

Objective： To observe the effects of benzbromarone combined with allopurinol on blood uric acid level in treatment of patients with stable gout. Methods： 136 patients with stable gout were randomly divided into control group（only treated with allopurinol） and observation group（treated with benzbromarone combined allopurinol） with 68 patients in each group, and all the patients were treated for 8 weeks. The blood uric acid level, blood platelet and white blood cell of patients before and after treatment were respectively detected; as well as the adverse reactions of patients during treatment were recorded. Results： After treatment, the blood uric acid level of patients in observation group were obviously lower than patients in control group, the blood platelet and white blood cell were obviously higher（P〈 0.05）. There was no significant difference in the incidence of adverse reactions between observation group and control group during treatment（P 〉0.05）. Conclusions： Treating stable gout patients with benzbromarone combined allopurinol can obviously decline the blood uric acid level, and without increasing adverse reactions, so it is worthy of clinical spreading.